These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 7680986)
1. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Wiseman LR; McTavish D Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986 [TBL] [Abstract][Full Text] [Related]
2. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Wiseman LR; Goa KL Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457 [TBL] [Abstract][Full Text] [Related]
4. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. Bajetta E; Zilembo N; Barni S; Noberasco C; Martinetti A; Ferrari L; Schieppati G; Buzzoni R; Jirillo A; Amichetti M; D'Aprile M; Comella G; Bichisao E; Bolelli GF; Attili A; Bombardieri E Ann Oncol; 1997 Jul; 8(7):649-54. PubMed ID: 9296217 [TBL] [Abstract][Full Text] [Related]
5. Formestane in the treatment of advanced postmenopausal breast cancer. Possinger K; Jonat W; Höffken K Ann Oncol; 1994; 5 Suppl 7():S7-10. PubMed ID: 7873464 [TBL] [Abstract][Full Text] [Related]
6. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability. Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786 [TBL] [Abstract][Full Text] [Related]
7. Formestane: effective therapy in postmenopausal women with advanced breast cancer. Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Martinetti A; Ferrari L; Bartoli C; Sacchini V; Attili A; Lepera P Ann Oncol; 1994; 5 Suppl 7():S15-7. PubMed ID: 7873456 [TBL] [Abstract][Full Text] [Related]
8. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Dowsett M; Mehta A; King N; Smith IE; Powles TJ; Stein RC; Coombes RC Eur J Cancer; 1992; 28(2-3):415-20. PubMed ID: 1591054 [TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced breast cancer with formestane. Murray R; Pitt P Ann Oncol; 1994; 5 Suppl 7():S11-3. PubMed ID: 7873455 [TBL] [Abstract][Full Text] [Related]
10. Formestane: an effective first-line endocrine treatment for advanced breast cancer. Zilembo N; Bajetta E; Noberasco C; Buzzoni R; Vicario G; Bono A; Laffranchi A; Biasi G; Dolci S; Bichisao E J Cancer Res Clin Oncol; 1995; 121(6):378-82. PubMed ID: 7797604 [TBL] [Abstract][Full Text] [Related]
11. Formestane as treatment of advanced breast cancer in elderly women. Zilembo N; Buzzoni R; Celio L; Noberasco C; Ferrari L; Laffranchi A; Vicario G; Dolci S; Bajetta E Tumori; 1994 Dec; 80(6):433-7. PubMed ID: 7900232 [TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Dowsett M Ann Oncol; 1994; 5 Suppl 7():S3-5. PubMed ID: 7873460 [TBL] [Abstract][Full Text] [Related]
13. Pilot study of formestane in postmenopausal women with breast cancer. Joseph JK; Lim AK Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135 [TBL] [Abstract][Full Text] [Related]
14. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E Oncology; 1995; 52(6):454-7. PubMed ID: 7478430 [TBL] [Abstract][Full Text] [Related]
15. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852 [TBL] [Abstract][Full Text] [Related]
16. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma. Nisslein T; Freudenstein J Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of formestane in breast cancer patients. Lønning PE; Geisler J; Johannessen DC; Gschwind HP; Waldmeier F; Schneider W; Galli B; Winkler T; Blum W; Kriemler HP; Miller WR; Faigle JW J Steroid Biochem Mol Biol; 2001 Apr; 77(1):39-47. PubMed ID: 11358673 [TBL] [Abstract][Full Text] [Related]
19. Severe immune thrombocytopenia during formestane treatment. Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809 [TBL] [Abstract][Full Text] [Related]
20. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]